Compare
Nektar Therapeutics vs Agios Pharmaceuticals, Inc. vs Q32 Bio Inc. vs Ocular Therapeutix, Inc
| Latest fiscal year | Nektar Therapeutics NKTR | Agios Pharmaceuticals, Inc. AGIO | Q32 Bio Inc. QTTB | Ocular Therapeutix, Inc OCUL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $55.23M | $54.03M | $53.74M | $51.95M |
| Revenue growth (YoY) | -43.9% | +48.0% | n/a | -18.5% |
| Gross margin | n/a | 88.3% (computed) | n/a | 87.3% (computed) |
| Operating margin | -253.7% | -873.9% | 31.5% | -519.8% |
| Net margin | -297.1% | -764.0% | 55.5% | -511.9% |
| Net income | -$164.08M | -$412.78M | $29.82M | -$265.94M |
| EPS (Diluted) | -$9.73 | -$7.12 | $2.42 | -$1.42 |
| Operating cash flow | -$208.51M | -$372.98M | -$33.54M | -$204.88M |
| Free cash flow | -$208.68M | -$377.29M | -$33.54M | -$216.89M |
| Cash & equivalents | $15.12M | $89.13M | $48.30M | $737.06M |
| Total assets | $280.41M | $1.30B | $61.78M | $808.06M |
| Total liabilities | $190.57M | $104.11M | $19.76M | $153.75M |
| Shareholders' equity | $89.83M | $1.19B | $42.01M | $654.31M |
| Return on year-end equity | -182.6% | -34.6% | 71.0% | -40.6% |
| Shares outstanding | 20.38M | 58.45M | 12.86M | 215.93M |
Revenue, most recent five fiscal years
| Fiscal year | Nektar Therapeutics | Agios Pharmaceuticals, Inc. | Q32 Bio Inc. | Ocular Therapeutix, Inc |
|---|---|---|---|---|
| Latest | $55.23M Ended 2025-12-31 | $54.03M Ended 2025-12-31 | $53.74M Ended 2025-12-31 | $51.95M Ended 2025-12-31 |
| 1 year earlier | $98.43M Ended 2024-12-31 | $36.50M Ended 2024-12-31 | $0 Ended 2024-12-31 | $63.72M Ended 2024-12-31 |
| 2 years earlier | $90.12M Ended 2023-12-31 | $26.82M Ended 2023-12-31 | -$6.65M Ended 2023-12-31 | $58.44M Ended 2023-12-31 |
| 3 years earlier | $92.06M Ended 2022-12-31 | $14.24M Ended 2022-12-31 | n/a | $51.49M Ended 2022-12-31 |
| 4 years earlier | $101.91M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a | $43.52M Ended 2021-12-31 |